Title : Phase II trial to investigate the safety and efficacy of orally applied niclosamide in patients with metachronous or sychronous metastases of a colorectal cancer progressing after therapy: the NIKOLO trial.

Pub. Date : 2018 Mar 15

PMID : 29544454






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 The Food and Drug Administration (FDA)-approved anti-helminthic drug niclosamide is known to intervene in the Wnt/beta-catenin pathway signaling, leading to reduced expression of S100A4 linked to restricted in vivo metastasis formation. Niclosamide S100 calcium binding protein A4 Homo sapiens